|1.||Welch, Jan: 2 articles (02/2015 - 08/2012)|
|2.||Morgan, Louise: 2 articles (02/2015 - 08/2012)|
|3.||Brittain, Bernadette: 2 articles (02/2015 - 08/2012)|
|4.||Star, Robert A: 1 article (04/2008)|
|5.||Rubin, Mark A: 1 article (04/2008)|
|6.||MPSA Consortium: 1 article (04/2008)|
|7.||Slawin, Kevin: 1 article (04/2008)|
|8.||Getzenberg, Robert H: 1 article (04/2008)|
|9.||Liu, Brian C-S: 1 article (04/2008)|
|10.||Mullins, Chris: 1 article (04/2008)|
03/01/2007 - "With regard to the whole range of t-PSA (n = 92; 0.1 - 88.4 microg/L) the diagnostic selection between prostate carcinoma (CaP) and benign disease (BPH) was significantly improved by PSAD (AUC = 0.803) and mPSAD (Vp) (AUC = 0.806) (p < or = 0.003) compared to t-PSA und mPSA (Vp) (AUC = 0.531). "
|2.||Wounds and Injuries (Trauma)
02/01/2015 - "MPSA victims reported a higher rate of stranger assaults, higher rates of vaginal, anal and oral rapes, more rapes at multiple anatomical sites or multiple rapes and were more likely to sustain injuries, all of which put MPSA victims at higher risk of subsequent health problems. "
08/01/2012 - "Victims of MPSA were younger, less likely to be White, more likely to report previous self-harm and more likely to sustain injuries than victims of SPSA. "
|3.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
04/01/2008 - "The MTOPS Prostatic Samples Analysis (MPSA) Consortium was established to identify and validate molecular markers that may better define benign prostatic hyperplasia related pathologies, identify risk of progression of lower urinary tract symptoms, and predict response to drug therapy using the MTOPS archive. "
04/01/2008 - "To date the MPSA has identified a number of promising biomarkers as well as other molecular and cellular changes associated with benign prostatic hyperplasia. "
04/01/2008 - "A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium."
|1.||Biological Markers (Surrogate Marker)
|1.||Drug Therapy (Chemotherapy)